According to the company, AurPROFILER enables researchers to rapidly evaluate target, cell and drug profiles using bio-assays derived from the activity data found in Aureus Pharma’s AurSCOPE target
Dr Stromatt replaces Daniel Burge who will be resigning his position with the company for personal reasons in late August 2008. Most recently, Dr Stromatt was executive vice
The Edema4 trial, conducted under a special protocol assessment granted by the FDA, achieved statistically significant improvements in the intent-to-treat population in primary and secondary endpoints. DX-88 was
Bupropion hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL for the treatment of major depressive disorder. Douglas Boothe, CEO of Actavis,
Mr Zhou was a partner and managing director of Eos Funds, where he directed investments in Chinese companies which intended to list on US and Canadian exchanges. Mr
In addition, Mr Renz will play a key role in developing strategic partnerships and alliances. He will report directly to Branislav Vajdic, who continues as the company’s CEO.
The license is for tests related to the detection, monitoring and risk assessment of pre-eclampsia, a leading cause of maternal death. In addition, Beckman Coulter obtained rights to
Led by Eleftherios Diamandis, the project team in Toronto will use Thermo Fisher Scientific’s mass spectrometers, in collaboration with the Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center
The new company will retain the name Noteworthy Medical Systems and will serve a combined customer base of more than 1,200 practices, 5,700 healthcare providers and 12,000 users
The program is composed of two separate Phase III clinical trials involving a total of 540 patients and being carried out in parallel in a total of 14
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.